Psoriatic Arthritis – Landscape & Forecast – Disease Landscape & Forecast
The psoriatic arthritis (PsA) therapy market has become increasingly dynamic with the recent launches of several targeted agents—AbbVie’s Rinvoq and Skyrizi and UCB’s bimekizumab. Furthermore, a series of approvals expected in the next decade will likely present a challenge to the dominance of the TNF inhibitors, especially as biosimilars are increasingly accepted as alternatives to more-expensive branded therapies, and drugs with novel mechanisms of action become available. Interleukin (IL)-17 and IL-23 inhibitors, in particular, are poised to garner substantial sales and, with the diagnosis and drug-treatment rate anticipated to remain relatively steady, could threaten the positions of current market leaders. The impending entry of the first TYK2 inhibitor (BMS’s deucravacitinib) and an IL-23 inhibitor (Sun Pharma’s tildrakizumab) will also create interesting market dynamics.
Questions answered
- What impact will current and emerging biosimilars have on the PsA therapy market in the coming years? How will physicians in the various markets under study react to these less-expensive therapies?
- How will newer agents, especially those offering an alternative to the market-leading TNF inhibitors, change the PsA therapy market? What are physician perceptions of these therapies?
- Which emerging therapies do dermatologists and rheumatologists consider the most promising for PsA? Which novel mechanisms of action are considered good clinical targets for this disease?
- Which unmet needs remain in the treatment of PsA? Will emerging therapies fulfill these needs, and will they be competitive with biosimilars and entrenched branded therapies?
Content highlights:
Geographies: United States, EU5, Japan.
Primary research: 31 country-specific interviews with thought-leading dermatologists and rheumatologists supported by survey data collected for this and other Clarivate research.
Epidemiology: Number of PsA patients by country, including diagnosed and drug-treated populations.
Forecast: 10-year, annualized, drug-level sales and patient share of key PsA therapies to 2032, segmented by brands / generics.
Emerging therapies: Phase 3/PR: 2 drugs; Phase 2: 7 drugs.
Product description
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Solution enhancement
Disease Landscape & Forecast is updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.
Disease Landscape & Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Psoriatic Arthritis - Landscape & Forecast - Disease Landscape & Forecast
- Key Findings
- Key Updates
- Market Outlook
- Forecast
- Etiology and Pathophysiology
- Epidemiology
- Current Treatment
- Unmet Need Overview
- Drug Pipeline
- Emerging Therapies
- Access and Reimbursement Overview
- Methodology
- Appendix
- Key Findings
Vaishnavi Dhiman, M.Sc., Associate Healthcare Research & Data Analyst, Immune and Inflammation. Before joining Clarivate, Ms. Dhiman was a research analyst at Prescient Healthcare Group and a drug safety associate (Regulatory) at Parexel International. She has substantial experience in secondary research, clinical trials and regulatory analysis of drug products, and competitive intelligence. She holds an M.Sc. and a B.Sc. (Honors) in microbiology from Panjab University in Chandigarh, India.
Navya Vardhan, M.Sc., Epidemiologist, Epidemiology. She obtained her M.Sc. in biostatistics and demography from the International Institute for Population Sciences in Mumbai. She also holds a B.Sc. in mathematics.